TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07142954: A Longitudinal, Prospective Epidemiology Study in Alzheimer's Disease: Assessing Neurocognitive and Biomarker Changes and Health Outcomes in Individuals at Risk for Symptoms of Alzheimer's Disease (ANCHOR-AD)

Sponsor: Eli Lilly and Company · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 3400 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$23,401,600

Rescue Site Savings

+$15,430,430

Unlock Full NCT07142954 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07142954 Rescue Dossier →